The gastroparesis treatment market shall be defined as the portion of the healthcare industry devoted to management and treatment of gastroparesis, a disease which is associated with delayed gastric emptying but without any evidence of mechanical obstruction. This condition causes severe complications of the digestive tract, such as nausea, vomiting, swelling and finally poor nutrition. This topic involves numerous products which include drugs to stimulate stomach muscles, changes in diet and other surgeries such as gastric electrical stimulation. Furthermore, the findings of this systemic review provide evidence in relation to management of gastroparesis in order to increase knowledge and practice for improved patient quality of life and minimize potential complications in the long run.

The gastroparesis treatment market has been growing due to the rising incidence of GI disorders – most commonly in diabetic patients, which cause gastroparesis. The increase in the customer base of diabetes and more specifically Type 1 has demanded more ways towards gastroparesis cure. Furthermore, awareness and knowledge of gastrointestinal diseases have improved due to heightened publicity of their symptoms as well as increased modern diagnostic techniques hence early diagnosis and subsequent management of the disease. Some of the new antiemetic segments, prokinetic agents and drugs that treats nausea have opened new opportunities to the firms in the market.

Also, the rise in the healthcare expenditure towards tackling gastroparesis in the emerging nations and ongoing research activities in enhancing gastroparesis management profiles are the factors that fuel the market. They are in the process of creating better value through innovations for example in matters touching on surgical techniques as well as coming up with new formulations that are better for patients. Another advantage has been the increasing trial in clinic trials aimed at new drugs for the treatment of both diabetic and idiopathic gastroparesis thus increasing the options for patients globally.

Gastroparesis Treatment Market Trend Analysis:

Growing Adoption of Prokinetic Agents

• Due to the increasing popularity of gastroparesis among patients, the use of prokinetic agents, which can be considered one of the trends in the market, has grown louder. Such agents include metoclopramide and domperidone that are commonly used to stimulate the muscles of the stomach and promote the movement of the stomach. Over the last few years, prokinetic drugs have undergone a process of “fine-tuning” to decrease adverse effects while increasing efficacy. The run for prokinetic agents has also increased due to their approval and availability in the markets other the Asia Pacific, especially in North America and Europe. Moreover, the combination of prokinetics with other therapeutic regimens such as antiemetic agents has indicated the potential for enhancing patient care management a factor that is expected to foster the growth of the market.

Experiencing a rise in diabetes prevalence

• New entrants in the gastroparesis treatment market find the emerging economies full of growth potential. India, China, and Brazil have indicated increased trends in the number of individuals with diabetes through changes in diets, level of physical activities, and rising obesity levels. The reported increase in the diabetic population which is an essential risk factor for gastroparesis is fueling the elaboration for appropriate treatments for the disease. Moreover, the cost of health care is rising in these areas, the government and private organizations are putting more capital into the enhanced medical framework and treatment regimens. The market which is relatively unsaturated with products accompanied by a recent increase in people’s awareness on the health of their digestive systems means that emerging markets should be strategic focuses of multinational pharmaceutical companies.

Gastroparesis Treatment Market Segment Analysis:

Gastroparesis Treatment Market is Segmented based on type, Drug Class, Treatment, and Region

By Type, Diabetic segment is expected to dominate the market during the forecast period

• The diabetic segment is anticipated to hold the largest market share for gastroparesis treatment in the forecast period due to the fact that diabetes and especially type 2 diabetes is on the rise and has an increased risk for gastroparesis as a complication. Diabetic gastroparesis occurs when diabetic nerve damage affects the muscles of the stomach and small intestine leading to slow gastric emptying. Due to the growing elder population global prevalence of diabetes mellitus has escalated resulting in the need for separate treatment programs as well as prokinetic agents for disorder such as diabetic gastroparesis and antiemetic drugs. Technologically, diabetic care and diagnosis have enhanced the management of gastroparesis pharmaceutical industries invest in the manufacture of a specialized medicines for this segment.

By Drug Class, Prokinetic agents segment expected to held the largest share

• The research report is intended to service the prokinetic agents segment as the largest growth contributor in the gastroparesis treatment market throughout the forecast period. This medication for example the metoclopramide and domperidone is used to improve the contractions of the stomach lining and thus hasten the emptying of food from the stomach. It should be mentioned that prokinetic agents are currently considered to be the most effective method of gastroparesis treatment since they affect the problem place – delayed gastric emptying. Due to constant research to enhance their safety and effectiveness prospects and addition of new and improved prokinetic agents having fewer adverse reactions, the global prokinetic agents segment is expected to retain its dominance in the overall growth projection and increased development in the future years.

Gastroparesis Treatment Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America has been the largest market in the gastroparesis treatment market in 2023. The analysis of the regions` influence can be explained by several factors, such as a high level of diabetes cases, the progression of healthcare, and such significant market participates in the development of the gastroparesis solution. On the same note, the United States is outstanding in diagnosing and treating the condition, which has attributed to the large share in the regional market. Currently, the North American region captured about 45 percent of global market share in 2023. It is backed up by large investment in research and development, especially in new drugs and devices to better treat the symptoms of gastroparesis.

Active Key Players in the Gastroparesis Treatment Market

• Abbott Laboratories (USA)
• Allergan (Ireland)
• AstraZeneca plc (UK)
• Boston Scientific Corporation (USA)
• Cipla Ltd. (India)
• Evoke Pharma (USA)
• GlaxoSmithKline plc (UK)
• Ironwood Pharmaceuticals (USA)
• Johnson Johnson (USA)
• Medtronic (USA)
• Novartis AG (Switzerland)
• Pfizer Inc. (USA)
• Takeda Pharmaceutical Company (Japan)
• Teva Pharmaceuticals (Israel)
• Thera Vance Biopharma (USA)
• Other Active Players

Key Industry Developments in the Gastroparesis Treatment Market:

• In December 2022, A United States Patent No. 11,517,545 under the title "Treatment of Moderate and Severe Gastroparesis" has been issued by the United States Patent and Trademark Office (USPTO), according to a statement made by Evoke Pharma, Inc., utilizing GIMOTI.
• In April 2022, in a Phase 2A clinical trial with PCS12852, Processa Pharmaceuticals, Inc. recruited its first patient, a patient with moderate-to-severe gastroparesis.

CONTACT US:- 

INTROSPECTIVE MARKET MARKET 
CALL:- +91 91753-37569.
E-MAIL:- [email protected]